Q4 2025 Gene, Cell, & RNA Therapy Landscape Report

The report provides a data‑driven snapshot of a sector in transition. Covering global pipeline activity, regulatory progress, and investment trends, the report highlights where innovation is advancing—and where portfolios are becoming more selective.

Inside the report

Three new gene and RNA therapy approvals in Q4 2025
A modest pipeline contraction driven primarily by fewer preclinical programs
A sharp rebound in start‑up financing, signaling renewed investor confidence

First Name *

Last Name *

Company *

Job Title *

Business Email Address *

Country *

Business Phone

How Can We Help

fieldlabel

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.
サイトラインより、関連する製品・サービス・コンテンツに関する情報をお届けする場合があります。配信停止や受信内容の管理をご希望の場合は、プリファレンスセンターをご利用ください。

ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。

This report is valuable for

Biopharma leaders shaping R&D and portfolio strategy
Business development teams assessing partnering and acquisition opportunities
Investors and analysts tracking funding momentum and deal activity
Researchers and clinicians seeking a macro view of gene, cell, and RNA therapy trends

Related resources

NOV 21, 2025

Report

Citeline

Q3 2025 Gene, Cell, + RNA Therapy Landscape Report

Q3 2025 brought progress across the gene, cell, and RNA therapy landscape, marked by four new global approvals — one in each major therapeutic category.

OCT 11, 2024

Report

Clinical

ISCT Cell and Gene Therapy Global Regulatory Report H1 2024

The Cell and Gene Therapy Global Regulatory Report from ISCT and Citeline provides a global overview of the cell and gene therapy regulatory landscape.

JUN 13, 2024

Webinar

Citeline

Commercialization of Cell and Gene Therapy

This on-demand webinar, presented in collaboration with the Indian Pharmaceutical Alliance and featuring Citeline's Pooja Rana, offers an in-depth analysis of the commercial landscape for cell and gene therapies.

View all